BACKGROUND/AIMS: The cardiorenal syndrome is a complication in patients hospitalized with chronic heart failure (CHF). The β2-microglobulin (b2M) level is an index of decreased glomerular filtration rate (GFR), tissue turnover and inflammation. It is an emerging new predictive marker of cardiovascular events and mortality, but its role as a biomarker of cardiorenal remodeling and failure is still unknown. TIMP1, an endogenous tissue inhibitor of activated matrix metalloproteinases, is a biomarker of heart remodeling and failure. We aimed to evaluate the circulating profile of b2M and TIMP1 in CHF patients, in sedentary controls with no tissue remodeling and in veteran athletes with physiological cardiorenal remodeling and athlete's heart (AH). METHODS: We investigated the plasma levels of b2M and TIMP1 in 24 subjects with CHF without primitive renal disease, in 25 sedentary controls and in 30 veteran marathoners with AH over 50 years. RESULTS: The b2M and TIMP1 levels were higher in CHF patients, and there was a correlation between them (r = 0.5287, p < 0.0095). The b2M level correlated with the severity of cardiorenal impairment: with proBNP (r = 0.66, p > 0.0007), percent ejection fraction (r = -0.56, p = 0.0162) and GFR (r = 0.83, p < 0.0001). b2M was also correlated with TIMP1 in AH subjects (r = 0.7548, p < 0.0001) but not in controls. This correlation was independent from GFR in both CHF patients and sedentary controls. CONCLUSIONS: In CHF patients, the plasma levels of b2M and TIMP1 were linked together and correlated with the severity of cardiorenal failure. Moreover, a strong correlation between b2M and TIMP1 characterized cardiovascular remodeling not only in CHF patients but also in AH subjects. These findings suggest that clinicians should use b2M and TIMP1 as associated biomarkers of cardiorenal remodeling and failure.
BACKGROUND/AIMS: The cardiorenal syndrome is a complication in patients hospitalized with chronic heart failure (CHF). The β2-microglobulin (b2M) level is an index of decreased glomerular filtration rate (GFR), tissue turnover and inflammation. It is an emerging new predictive marker of cardiovascular events and mortality, but its role as a biomarker of cardiorenal remodeling and failure is still unknown. TIMP1, an endogenous tissue inhibitor of activated matrix metalloproteinases, is a biomarker of heart remodeling and failure. We aimed to evaluate the circulating profile of b2M and TIMP1 in CHFpatients, in sedentary controls with no tissue remodeling and in veteran athletes with physiological cardiorenal remodeling and athlete's heart (AH). METHODS: We investigated the plasma levels of b2M and TIMP1 in 24 subjects with CHF without primitive renal disease, in 25 sedentary controls and in 30 veteran marathoners with AH over 50 years. RESULTS: The b2M and TIMP1 levels were higher in CHFpatients, and there was a correlation between them (r = 0.5287, p < 0.0095). The b2M level correlated with the severity of cardiorenal impairment: with proBNP (r = 0.66, p > 0.0007), percent ejection fraction (r = -0.56, p = 0.0162) and GFR (r = 0.83, p < 0.0001). b2M was also correlated with TIMP1 in AH subjects (r = 0.7548, p < 0.0001) but not in controls. This correlation was independent from GFR in both CHFpatients and sedentary controls. CONCLUSIONS: In CHFpatients, the plasma levels of b2M and TIMP1 were linked together and correlated with the severity of cardiorenal failure. Moreover, a strong correlation between b2M and TIMP1 characterized cardiovascular remodeling not only in CHFpatients but also in AH subjects. These findings suggest that clinicians should use b2M and TIMP1 as associated biomarkers of cardiorenal remodeling and failure.
Authors: S Hinan Ahmed; Leslie L Clark; Weems R Pennington; Carson S Webb; D Dirk Bonnema; Amy H Leonardi; Catherine D McClure; Francis G Spinale; Michael R Zile Journal: Circulation Date: 2006-04-24 Impact factor: 29.690
Authors: Brad C Astor; Tariq Shafi; Ron C Hoogeveen; Kunihiro Matsushita; Christie M Ballantyne; Lesley A Inker; Josef Coresh Journal: Am J Kidney Dis Date: 2012-02-04 Impact factor: 8.860
Authors: Antonio Pelliccia; Norimitsu Kinoshita; Cataldo Pisicchio; Filippo Quattrini; Fernando M Dipaolo; Roberto Ciardo; Barbara Di Giacinto; Emanuele Guerra; Elvira De Blasiis; Maurizio Casasco; Franco Culasso; Barry J Maron Journal: J Am Coll Cardiol Date: 2010-04-13 Impact factor: 24.094
Authors: Johan Sundström; Jane C Evans; Emelia J Benjamin; Daniel Levy; Martin G Larson; Douglas B Sawyer; Deborah A Siwik; Wilson S Colucci; Peter W F Wilson; Ramachandran S Vasan Journal: Eur Heart J Date: 2004-09 Impact factor: 29.983
Authors: Logan J Worke; Jeanne E Barthold; Benjamin Seelbinder; Tyler Novak; Russell P Main; Sherry L Harbin; Corey P Neu Journal: Adv Healthc Mater Date: 2017-09-07 Impact factor: 9.933
Authors: Daniel H Katz; Usman A Tahir; Debby Ngo; Mark D Benson; Yan Gao; Xu Shi; Matthew Nayor; Michelle J Keyes; Martin G Larson; Michael E Hall; Adolfo Correa; Sumita Sinha; Dongxiao Shen; Matthew Herzig; Qiong Yang; Jeremy M Robbins; Zsu-Zsu Chen; Daniel E Cruz; Bennet Peterson; Ramachandran S Vasan; Thomas J Wang; James G Wilson; Robert E Gerszten Journal: Circ Genom Precis Med Date: 2021-05-21
Authors: Li Ma; Na Zhou; Rongjun Zou; Wanting Shi; Yuanyuan Luo; Na Du; Jing Zhong; Xiaodong Zhao; Xinxin Chen; Huimin Xia; Yueheng Wu Journal: Front Cell Dev Biol Date: 2021-02-25
Authors: Zachary T Hilt; Daphne N Pariser; Sara K Ture; Amy Mohan; Pearl Quijada; Akua A Asante; Scott J Cameron; Julie A Sterling; Alyssa R Merkel; Andrew L Johanson; Jermaine L Jenkins; Eric M Small; Kathleen E McGrath; James Palis; Michael R Elliott; Craig N Morrell Journal: JCI Insight Date: 2019-03-07